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Abstract
Next-generation sequencing (NGS) technologies represented the next step in the evo-
lution of DNA sequencing, through the generation of thousands to millions of DNA 
sequences in a short time. The relatively fast emergence and success of NGS in research 
revolutionized the field of genomics and medical diagnosis. The traditional medicine 
model of diagnosis has changed to one precision medicine model, leading to a more accu-
rate diagnosis of human diseases and allowing the selection of molecular target drugs 
for individual treatment. This chapter attempts to review the main features of NGS tech-
nique (concepts, data analysis, applications, advances and challenges), starting with a 
brief history of DNA sequencing followed by a comprehensive description of most used 
NGS platforms. Further topics will highlight the application of NGS towards routine 
practice, including variant detection, whole-exome sequencing (WES), whole-genome 
sequencing (WGS), custom panels (multi-gene), RNA-seq and epigenetic. The potential 
use of NGS in precision medicine is vast and a better knowledge of this technique is nec-
essary for an efficacious implementation in the clinical workplace. A centralized chapter 
describing the main NGS aspects in the clinic could help beginners, scientists, researchers 
and health care professionals, as they will be responsible for translating genomic data 
into genomic medicine.
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1. Introduction
Precision medicine is a new way of practising medicine, which has been gaining strength in 
recent years, is based on the individual characteristics of each patient (genetic, environmental, 
behavioural) to optimize and customize strategies for prevention, detection and therapy [1, 
2]. The molecular knowledge has contributed strongly to the advancement of precision medi-
cine, providing specific strategies for target therapies and diagnosis of patients with cancer, 
Mendelian diseases and others. Statistics indicated that traditional clinical practices some-
times lead to poor health outcomes and also a waste of medical resources. It is estimated that 
about 75 billion US dollars per year (30% of health care expenditure) are destined for unneces-
sary or ineffective treatments in the USA [3].
As a result of the genome project, many molecular tools have been developed and allow 
medical and scientific groups to improve patient management based on a better under-
standing of disease biology, providing a more specific and accurate prevention and treat-
ment of diseases [4]. Precision medicine redefines the way traditional medicine is practised. 
There is a great deal of investment nowadays in prevention using these new technologies, 
as opposed to old medicine based on treatment since the disease was already evident or 
irreversible [2].
In recent times, Sanger sequencing, referred to as a ‘first-generation’ sequencing method, 
has partly been replaced by ‘next-generation’ sequencing (NGS) methods [4, 5]. NGS allows 
identifying biomarkers for early diagnosis as well as for personalized treatments. The emer-
gence of NGS has changed the way clinical research, basic and applied science are done. The 
NGS allows producing millions of data with a smaller investment [4, 6]. Among the available 
NGS applications, one of them will be the resequencing of the human genome and the better 
genetic understanding of various human diseases. A great challenge will be the interpreta-
tion of this great number of data and its translation for the medical application [6]. One of the 
major near-term medical impact of the NGS revolution will be the elucidation of mechanisms 
of human pathogenesis, leading to improvements in the diagnosis and the selection of treat-
ment and prevention. Thanks to second-generation sequencing technologies, it has become 
easier to sequence the expressed genes (‘transcriptomes’), known exons (‘exomes’) and com-
plete genomes of patient’s samples [7].
This chapter encompasses revised concepts, applications, advances, limitations and the his-
tory of technological advances until the emergence of NGS technique in the era of precision 
medicine, starting with a brief history of DNA sequencing followed by a comprehensive 
description of most used NGS platforms, sequencing chemistries methodology and general 
workflows. Further topics will highlight the application of NGS towards routine practice, 
including variant detection, whole-genome sequencing (WGS), whole-exome sequencing 
(WES) and multi-gene panels. A centralized chapter describing the main NGS features in the 
clinic could help beginners, scientists, researchers and health care professionals, as they will 
be responsible for translating genomic data into genomic medicine.
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2. From Sanger to NGS sequencing
In 1908, Garrod introduced his concept ‘the inborn error of metabolism’ that changed the 
areas of biochemistry, genetics and medicine [8]. His principal contribution was the under-
standing about the relationship between gene-enzyme, the molecular basis of genetic diseases. 
Although today this concept is considered outdated because of discoveries like RNA splicing, 
RNAi and others, its development allowed the researchers to understand how changes in 
DNA sequence could cause genetic disease. This finding increased the interest of scientists to 
know about human DNA sequence and mutations.
The search to know the nucleotide sequence of DNA began in the 1960s with several studies 
that demonstrated new methods with different strategies [9–13], but it was in 1977 that Sanger 
developed the method called ‘Chain-termination’ that became the most used method (first 
generation) to sequencing DNA (Figure 1). The method consisted of the use of dideoxynucle-
otides (ddNTPs), which are deoxynucleotide analogs (dNTPs) that disrupt DNA synthesis, 
and the separation of the different DNA fragments in a gel. These special nucleotides were 
radiolabeled and therefore the sequence could be inferred after the disclosure of gel autoradi-
ography [14]. Numerous modifications have been made in this technique to make the method 
more efficient, robust and sensitive. Among them are the substitution of nucleotide radiola-
beled to fluorescence that allowed the sequencing reaction to occur in one tube [15], the devel-
opment of the polymerase chain reaction [16], the separation of DNA fragments by capillary 
electrophoresis [17] and later the development of equipment that allowed the sequencing of 
Figure 1. Timeline of DNA sequencing evolution from Sanger to NGS and the cost per raw megabase of DNA sequenced 
[17]. Equipment of all generations is still being improved and released commercially. Dot: milestones; rectangle: 
equipments; White: first-generation sequencing; Light gray: second-generation sequencing; Dark gray: third-generation 
sequencing.
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more complex genomes. The most famous sequencing project, the Human Genome Project, 
produced in 13 years 3 billion of sequenced bases with the estimated cost around $2.7 billion 
[18]. To date, Sanger is still the gold-standard method in diagnostic tests and although the 
most recent methods have a much higher processing capacity, confirmation of some findings 
is made using this method.
The second generation of DNA sequencing can be defined as the era of the parallel mas-
sive sequencing on a micro scale. The Pyrosequencing method developed by Nyrén and 
colleagues in 1996 was the starting point for this generation. This technique differed sub-
stantially from previous ones because it did not use radio or fluorescence-labelled nucleo-
tides and there was no need of electrophoretic run. The method is based on the action of two 
enzymes: ATP sulfurylase and luciferase. ATP sulfurylase converts pyrophosphate released 
in nucleotide incorporation into an ATP molecule that is used by luciferase substrate. This 
process releases light signal in proportion to the amount of nucleotides incorporated, and 
the sequence can be determined according to the serial addition of nucleotides [19]. Later on, 
this technology was improved and licensed generating the first ‘second-generation’ equip-
ment, known as 454 (Roche). Among the improvements made, there are the DNA binding 
in beads through an adapter and the amplification of this DNA in water-in-oil microreac-
tors (emulsion PCR). These changes and the use of microplates that compartmentalized the 
process and high-definition detection systems dramatically increased the amount of DNA 
sequenced and defined the second generation [20]. The disadvantage of this technology is 
related to homopolymer regions because of difficulty in interpreting the signal strength when 
five or more nucleotides are incorporated in a single wash cycle. Other technologies were 
then developed, such as that used by Illumina which consists of binding the DNA in a flow-
cell through adapters, and the parallel massive amplification occurs in clusters for each DNA 
strand that was originally bound in the flow-cell, called bridge-amplification. This process 
generates paired-ends sequences that are an advantage over other methodologies, since they 
improve the accuracy of mapping, mainly in repetitive regions or where DNA rearrange-
ments or gene fusions occur. The method uses ‘reversible terminator chemistry’ which is a 
modified fluorescent dNTP that reversibly blocks DNA synthesis, so the addition of each 
nucleotide can be synchronized and monitored by a charge-coupled device (CCD) sensor 
[21]. This is one of the most accurate and with lowest error rate of sequencing methodologies 
used currently; however, it generally requires higher DNA concentration. Another method-
ology is based on oligonucleotide ligation sequencing known as SOLiD and developed by 
Applied Biosystems (now Thermo Fisher Scientific). The method does not do sequencing by 
synthesis but by ligation of oligonucleotides fluorescence-labelled. Each probe is an octamer, 
which contains two known nucleotides in the 3’ end followed by six degenerated nucleotides 
with one of four fluorescent labels linked to the 5’ end. After probe annealing and ligation, 
fluorescent dye is cleavage and a new probe is ligated. Multiple cycles are performed accord-
ing to the read length. The template from primer (n) is removed and the second round of 
sequencing is performed with a primer complementary to the (n-1) position [22]. This method 
shows good results; however, it is considered slow compared to the others and therefore was 
replaced by Ion Torrent (Thermo Fisher Scientific) technology. Like 454, the DNA bound in 
a bead is massively amplified by emulsion PCR and detection occurs in picotiter wells using 
complementary metal-oxide-semiconductor (CMOS) due to the pH difference caused by the 
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release of H+ ions in the nucleotide incorporation. This methodology is the first to use a detec-
tion method that does not work with light signal [23]. The advantage of this technology is the 
speed of the process and the low cost of the equipment; however, it has the same problem 
about the detection of homopolymers. The second generation of the sequencing was marked 
by the high capacity of the sequencers in the generation of data in a single run and conse-
quently the computational development-like bioinformatics tools to analyse them. The cost 
of sequencing decreased dramatically at this stage. At the beginning of the first-generation 
sequencing (2001), the approximate cost per megabase sequenced was $5292.39 and at the 
end of this phase (2007) was $397.09, while in the second generation the sequencing cost was 
$102.13 (2008) and at the end (2015) only $0.014 [18], showing a more pronounced decline in 
this phase (Figure 1).
There are some discussions about which technology marked the beginning of the third gen-
eration [24–27]. In this review, we will consider the technology of single-molecule sequencing 
(SMS), which has no need to amplify the DNA. The first technology to use SMS was ‘virtual 
terminators’ based on a method very similar to Illumina, but a single DNA molecule is fixed in 
a flow-cell with 25 channels. The process occurs in cycles where the dNTPs are incorporated 
and the corresponding fluorescence is captured by a CCD camera. This process generates 
short readings (25 bp) and it is considered slow and there is a lot of noise in the signal [28]. 
Despite being the first third-generation sequencing technology, its history was brief because 
the company Helicos Biosciences filed for Chap. 11 bankruptcy. Another technology devel-
oped is the ‘single molecule real time’ (SMRT) that is commercialized by Pacific Biosciences. 
The SMRT consists of the immobilization of a single molecule in a chamber called ‘zero-mode 
waveguide (ZMW)’ where the incorporation of the fluorescent nucleotides occurs. ZMW 
allows the incorporation of each nucleotide to be monitored in real time and without interfer-
ence from other light signals. The reads are very long (40 kb) and allow detecting modified 
bases [29, 30]. Finally, the technology of ‘nanopores’ consists of conducting a molecule of 
DNA or RNA through a biological or not nanopore. The detection occurs due to differences in 
the current of ions generated by each nucleotide. The reads are incredibly long (500 kb), and 
the process is extremely fast without the need for special nucleotides. The company Oxford 
Nanopore Technologies (ONT) is the first company to commercialize sequencers using this 
technology, including a portable version (MinION) that was used to sequence a mixture of 
bacteriophage, Escherichia coli and Mus musculus DNA at the international space station (ISS) 
[31]. In common, these technologies still have high error rates that are improving with the 
development of technology. Its main use today is to aid in the assembly of complex regions of 
the genome where gene fusions, large deletions and insertions and repetitive regions occur. 
The third generation will further revolutionize precision medicine, enabling sequencing at 
lower cost and enabling this to occur virtually anywhere.
3. Clinical applications
In recent times, NGS has made possible a better understanding of genetic diseases and 
became a significant technological advance in the practice of diagnostic and clinical medicine 
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[32]. NGS allows the analysis of multiple regions of the genome in one single reaction and has 
been shown to be a cost-effective and an efficient tool in investigating patients with genetic 
diseases. Genetic data produced via NGS provides significant benefits to medical practice 
including accurate identification of biomarkers of disease, detecting inherited disorders and 
identifying genetic factors that can help predict responses to therapies [32, 33]. However, rec-
ommendations on clinical implementation of NGS that are still in discussion and that hamper 
its use in the genetic clinic. A variety of molecular diagnostic test use sequencing technology, 
such as single- and multi-gene panel tests, cell-free DNA for non-invasive prenatal testing, 
whole-exome sequencing (WES), whole-genome sequencing (WGS). Considering that the use 
of NGS as a diagnostic tool is recent, there are challenges including when to order, on whom 
to order and how to interpret and communicate the results to the patient and family [32]. 
Therefore, it is necessary to understand the application, strength and limitations of the dif-
ferent approaches to recognize which one is the most suitable for your case. In the following 
topics, we will emphasize common applications of this technology into clinical practice.
3.1. Multi-gene panels
The traditional approach still holds great value for many disorders. Single-gene testing is 
indicated when the clinical features for a patient are typical for a particular disorder and the 
association between the disorder and the specific gene is well established and has the mini-
mal locus heterogeneity [34]. However, many genetic conditions are intractable to diagnostic 
evaluation, mainly because of the clinical variability and genetic locus heterogeneity, such as 
cardiomyopathies, epilepsy, congenital muscular dystrophy, X-linked intellectual disability 
and cancer susceptibility in families with atypical phenotypes [35]. The diagnostic process is 
exhausted, with clinical assessment followed by sequential laboratory testing, in most cases 
tests being negative. In cases with unidentified genetic conditions (e.g., developmental delay/
cognitive disability and autism spectrum disorders), the diagnosis rate can vary greatly [36] 
and a multi-gene panel is more appropriate. In diagnostic of cancer, for example, Tothill and 
colleagues [37] illustrate the application of these multi-gene panel by analysing samples of 
patients with cancers of unknown primary (CUP). The clinical management of patients with 
CUP is hampered by the absence of a definitive site of origin and this kind of NGS analysis 
could help to define new therapeutic options.
In multi-gene panel tests, many genes associated with a specific phenotype are sequenced 
and analysed concomitantly, decreasing cost and improving efficiency of genetic diagnostic 
[37]. The number and which genes will be evaluated for the same or similar indications may 
vary significantly among different clinical laboratories and several considerations need to be 
taken for gene inclusion. The majority of authors believe that only genes with a strong disease 
association should be included since the ability to interpret their findings is much better due 
to clinical evidence [38]. However, some authors consider including associated genes that 
have overlapping phenotypes for the purpose of differential diagnosis, or all possible genes 
that are remotely associated with the phenotype of interest with the objective of a better and 
faster diagnostic [34]. For cancer diagnostic, multi-gene panel may include high-penetrance 
genes as well as associated genes with a moderate increase in risk [35].
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The transition from single-gene to multi-gene testing should not compromise the sensitivity 
of the test to identify variants, mainly at genes that are responsible for a significant propor-
tion of the defects (core genes). The sensitivity of NGS does not depend only on horizontal 
coverage but the vertical coverage is important as well [39]. Additional genes will increase the 
chance of the diagnostic, but this should not be at cost of missing mutations that would pre-
viously have been detected by single-gene testing [38]. Sanger sequencing or other available 
techniques can help to solve this problem for filling in low-coverage and no-coverage regions.
3.2. Whole-genome and whole-exome sequencing
Whole-genome sequencing (also known as WGS, full-genome sequencing, complete genome 
sequencing or entire genome sequencing) is the process of determining the complete DNA 
sequence of an organism's genome at a single time. The major benefit of WGS is completed cov-
erage of the genome, including promoters and regulatory regions. In whole-exome sequenc-
ing (WES), all coding regions are sequenced with a relatively deeper depth. Compared to 
WGS, the major advantage of WES is a significant cost reduction [40].
Human genome comprises ~3 × 109 bp having coding and non-coding sequences. About 3 × 107 
bp (1%) (30 Mb) of the genome are the coding sequences [33]. It is estimated that 85% of the 
disease-causing mutations are located in coding and functional regions of the genome [41, 42]. 
For this reason, sequencing the complete coding regions (exome) has the power to uncover the 
causes of large number of rare, mostly monogenic, genetic disorders as well as predisposing 
variants in common diseases and cancers [33]. In 2009, Choi and colleagues first showed the 
value of WES in the medical practice by making genetic diagnoses of congenital chloride diar-
rhoea in patients suspected of Bartter syndrome, a renal salt-wasting disease. WES was con-
ducted on six patients who do not show any mutations in classic genes for Bartter syndrome. 
Results revealed homozygous deletion in SLC26A3 gene for all patients, which provided a 
molecular diagnosis of congenital chloride diarrhoea that was later confirmed on clinical eval-
uation. This result was the first to show the value of WES in making a clinical diagnosis and 
several similar studies have followed [43].
There are certain considerations to order WES instead of other NGS tools [32]. Although 
exomes are supposed to cover all the protein-coding regions of the genome, the average cov-
erage in many platforms tends to be between 85 and 95% [32, 44]. This means that a particular 
gene of interest that is closely linked to patient’s phenotype may not be covered, completely 
or partially. There are many reasons that include poorly performing capture probes due to 
high GC content, sequence homology or repetitive sequences. A targeted approach, such as 
NGS single- or multi-gene panels, on the other hand, has higher or even complete cover-
age of all the specific genes by filling in the gaps with complementary technologies such as 
Sanger sequencing or long-range PCR. Besides offering a more comprehensive coverage of 
the ‘known’ phenotype-specific gene panels, this targeted approach also allows for deeper 
coverage of these genes compared to WES, which provides greater confidence in the vari-
ants detected. However, all NGS tools are still prone to sequencing artefacts, and Sanger 
sequencing is recommended to confirm the variants detected before returning the results to 
the patient [44]. In addition, the patient and their family need to be aware of all the nuances 
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related to WES and WGS [45]. It is important to let them know that the test may not yield posi-
tive results, and it is crucial to clarify that even positive results can offer diagnoses but do not 
improve prognosis and treatment.
To request an exam that uses the WES technique, one must start collecting as much informa-
tion as possible about the patient. It is important to have a detailed family history, phenotype 
condition, symptoms and also, if possible, the inheritance pattern of the suspected disease 
[46]. With the phenotype and pedigree information, a systematic review of literature and 
databases should be performed to guide the clinician on which gene(s) are crucial and must 
be analysed. In cases of genetic heterogeneity, targeted NGS may be the preferred approach. 
On the other hand, if the disease mechanism is unknown, WES may be the best choice [47].
WES can result in approximately 60,000–100,000 genetic variants that can be classified into 
pathogenic, benign or with uncertain significance (VUS) [48]. With WES, a single pathogenic 
variant that is probably the cause of the patient phenotype can be detected in about 20–36%. 
For the other cases, it is possible to find multiple candidate variants or even no one. If no 
candidate variants are found, there are many reasons for it that include poor coverage or 
the mutation residing outside the protein-coding region of the gene, clinical summary with 
insufficient information or the defect is not due to a simple nucleotide change in a single gene 
[49–53].
The outcome of an exome should be evaluated by a multidisciplinary team that is involved 
with each patient's case. A discussion is necessary between physicians, geneticists, and other 
health professionals about all the clinical and laboratory findings to make a link with phe-
notype, family history and symptoms. It is necessary to review the WES results, scientific 
literature and medical information [32]. If more than one candidate variant is detected, this 
multidisciplinary team must perform further evaluation(s) to determine which of the variant 
is causing the phenotype. Finally, if the test results are negative, reasons for this should be 
discussed in the report. As the use of this tool is becoming more frequent and more accessible, 
it is possible that in the near future new pathogenic variants and genetic syndromes will be 
described and characterized, which causes these negative results to be reanalysed within a 
few years [32].
In cases of suspicion of Mendelian disease, the exome sequencing is usually indicated for the 
detection of rare variants and samples from the patient and his/her parents could be needed. 
This is usually the standard setting in cases where the Sanger sequencing of the candidate 
gene gave negative result or so there are multiple genes that must be tested for the condition 
that would be costly and time consuming. In most cases, the results obtained from WES reach 
a molecular diagnosis but do not alter the management, treatment or prognosis [32, 54].
Targeted exome sequencing is becoming increasingly popular in oncology for assessing the 
full sequence of cancer-related genes. Targeted exome sequencing also facilitates sequencing 
at a greater depth, and thus the identification of subclonal mutations. Alternately, rather than 
sequencing the full exome sequence, it is possible to look at all the genes reported to be related 
to cancer in general. Although hotspot mutation testing facilitates large-scale sequencing of 
many samples, it does limit the knowledge that is acquired through sequencing because it 
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limits the evaluation to small regions in selected genes. Consequently, small, targeted NGS 
panels increase the possibility of omitting relevant mutations for which evaluation is not being 
conducted, thus limiting the clinical knowledge that is gained through WES. WES could high-
light novel insights into cancer mechanisms; identification of the DNA sequence of cancer 
cells in comparison with that of normal cells could help to reach an in-depth understanding 
of cancer. Using WES, it is also feasible to check germline and somatic mutations in human 
cancers [33].
Approximately 5–10% of cancers are hereditary. WES allows testing of multiple genes at 
once and greatly improves the variation detection rate. Many patients with hereditary cancer 
have tested negative for one specific genetic variation, but with WES, it is easier to find caus-
ative mutations. In a study of 300 high-risk breast cancer families, it was found previously 
undetected mutations in 52 probands and the reduced sequencing costs and turnaround time 
made the approach even more practical in clinics [55].
To detect familial germline mutations, WGS might be advantageous for WES-negative cases 
in families with a great chance of carrying a genetic variant [56]. The major technical advan-
tage of WGS is that the specificity is theoretically 100% (average 95–98% in practice, practi-
cally without gaps) with a uniform coverage in the regions of interest (ROIs) throughout the 
input material. Thus, the chance of losing disease-causing variants due to technical errors is 
much lower with WGS [57–59]. The major challenge in applying this tool on a medical routine 
is the great costs, the complex pipeline for data analysis and data interpretation. However, 
in the near future, the costs of NGS should be lowered, studies on genetics over non-coding 
regions should be improved and more approach will be implemented. With that, WGS should 
be performed regularly for diagnostic in order to find the causative genetic variants [56].
Under gene panel analysis, about 70–92% of all cases remain negative, depending on the 
disease. It is expected that important genes will not be contemplated with these tools, mak-
ing WES and WGS analysis more appropriate to identify genetic variants in cases of familial 
syndromes. These tools (WES and WGS) have already been reported in identifying several 
risk genes for various types of cancer such as the PALB2 and ATM genes in pancreatic cancer, 
the hereditary pheochromocytoma susceptibility gene MAX [60] or the hereditary colorectal 
cancer moderate-risk genes POLD1 and POLE [61].
Nowadays, the clinical utility of WES and WGS as a generic test for mutation discovery for 
every genetic diagnostic question is not yet appropriate [62] and should be directed to specific 
patient groups [63]. This limitation is due to the high cost, the need of complex bioinformatics 
pipelines, large storage capacity and the expected high number of VUS detected.
3.3. RNA-sequencing
A transcriptome represents the complete set of RNA molecules from any genome at any time 
or condition and RNA plays essential role in several biological processes, including untrans-
lated RNA species such as microRNAs (miRNAs). RNA-sequencing (RNA-seq) consists of an 
in-depth RNA analysis through NGS technologies and became the state-of-art technique for 
transcriptomic [64]. A typical RNA-seq experiment consists of a good experimental design, 
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sample preparation, library construction, sequencing and data analysis. However, due to sev-
eral experimental options available, a careful planning and cost estimation is necessary before 
starting. These include number and type of replicates (technical vs. biological), sequencing 
platform (e.g. Illumina, Ion Torrent), library preparation method (e.g. rRNA depletion or 
mRNA enrichment; strand-specific or not; single or paired end), throughput, read length, 
sequencing depth and coverage. RNA-seq best practices can be found in Chap. RNA-seq: 
Applications and Best Practices from this book.
RNA-seq enables detection of novel genes and isoforms, gene fusions, splice and chimeric 
variants, genomic alterations and gene expression quantification. Although RNA-seq outper-
forms microarray in transcriptomic analysis [65], its clinical application is still in its infancy 
and, for instance, will not replace current approaches. RNA-seq is considered a complemen-
tary method depending on the needs and resources available, assisting clinicians in making 
decisions. In clinical practice, RNA measurement has applications across different areas in 
human health such as therapeutic selection, disease diagnostic and treatment [66].
Clinical diagnosis of infectious disease through RNA-seq is still rare, since quantitative PCR 
(RT-qPCR) assays are still the most common technique used for viral detection and geno-
typing. Applications of NGS in virology diagnostic can be used for analysis of patients with 
unexplained illness, especially during outbreaks and epidemics [67–70]. It also includes the 
identification of novel pathogens [71–74], viral community characterization [75–77], whole 
viral genome reconstruction [73, 78, 79], antiviral drug resistance [80–83], epidemiology [84–87] 
and transcriptomic [88–90]. The use of NGS in virology is increasing the knowledge of viral 
infection dynamics and their correlation with human health and treatment.
For oncology, RNA-based cancer diagnostics is being used by clinical oncologist to define 
tumour transcriptome due to its potential to guide treatment and drug therapy [91]. Its 
application are especially related to gene expression profile and variants, and gene fusions 
detection. The pathogenicity of gene fusions in cancer is well known. Most gene fusions are 
correlated with specific tumour subtypes, representing diagnostic biomarkers and leading to 
novel therapeutic opportunities and benefits [92–94]. Some pharmacological treatments are 
already in clinical use [94]. Key somatic DNA mutations can also represent cancer biomarkers 
and can be identified by transcriptomic mapping [95–98].
Gene expression in cancer is still quantified by non-sequencing methods (e.g. RT-qPCR and 
microarrays) [91]. RNA-seq can measure expression of tumour antigens or immune check-
point receptors and ligands after a given treatment, giving some answers about patient drug 
response [91, 99, 100]. Gene expression signatures can also be used for cancer types’ classifica-
tion that directly impact prognosis and treatment definition and response [100].
NGS can also be applied for circulating tumour RNA (ctRNA) discovery. The analysis of 
ctRNA in plasma is still in its beginning and presents specific challenges. ctRNA degrades 
faster than circulating tumour DNA (ctDNA) and needs to be purified rapidly or added in 
preservative solutions (e.g. TRIzol) and freezed at −80°C, not always an accessible technique 
to many clinical sites [101]. Despite these challenges, ctRNAs represent good biomarkers of 
early detection of multiple tumour types, such as breast, lung, prostate and colorectal cancers 
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[101–109]. NGS is a more powerful tool for ctRNA detection; however, RT-qPCR remains 
more usable for clinical diagnostic applications [110].
3.4. Epigenetics
An emerging field that has a huge impact on medicine and clinical diagnostic is epigenetics. 
The term was coined by Conrad Waddington in the 1940s and refers to the study of heritable 
changes in gene activity and expression that do not involve the DNA sequence itself, that is, a 
change in phenotype without a change in genotype [111, 112]. Additional information about 
epigenetics history can be found in Ref. [113]. Epigenetics mechanisms represent another 
layer of gene regulation and NGS allowed to understand the epigenetics status on a large 
scale and at a single base-resolution, including mainly DNA methylation, histone modifica-
tion and non-coding RNA (ncRNA)-associated silencing [111, 112].
DNA methylation was the first epigenetic mechanism identified and is the best known and 
the most frequent in human cancer. It involves covalent modification of cytosine through the 
addition of a methyl group to cytosines of CpG (cytosine/guanine) islands [111, 112]. This meth-
ylation is maintained by DNA methyltransferase (DNMTs) and plays roles for gene transcrip-
tional repression, transposable elements silencing and viral defence [111]. Unmethylated DNA 
is found in active regions of chromatin, and methylated DNA is found in inactive regions [112].
Post-translational histone modifications are markers for chromatin activity through acetyla-
tion and methylation of conserved lysine residues on the amino-terminal tail domains [112]: 
acetylation is found in active regions of chromatin, whereas hypoacetylation is found in inac-
tive euchromatic or heterochromatic regions [111, 112]. Enzymes involved in this process 
include histone deacetylases (HDACs), histone acetylases and histone methyltransferases 
[112]. These and other post-translational histone modification processes (e.g. phosphoryla-
tion) result in distinct histone modification patterns that form a ‘histone code’ [114].
Since epigenetic mechanisms regulate DNA accessibility, perturbations of the cell epigene-
tic pattern affect gene expression and can give rise to human diseases, that can be inherited 
or somatically acquired [111, 112]. Prader-Willi, Angelman and Beckwith-Wiedemann syn-
dromes, for example, are the best characterized congenital imprinting disorders [111, 115, 116].
4. Data analysis
Data analysis is a critical step of NGS tests. This analysis consist of a primary analysis, in 
which the base pairs are called and quality score are generated; a secondary analysis, numer-
ous reads are aligned to the human reference sequence; and a tertiary analysis which consists 
of variant calling and annotation [117]. Many databases are useful for helping the variant 
annotation, such as the 1000 Genome Project [118], dbSNP database [119], Clinvar—NCBI 
[120], LOVD—Leiden Open Variation Database [121], The Cancer Genome Atlas (TCGA) [122] 
and others. However, information from these sources can contain ambiguous and insufficient 
information. Variants detected should be reported according to Human Genome Variation 
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Society (HGVS) recommendations, with information of the human reference genome version 
and transcript information used to variant description [117]. The reference coding sequence 
should be preferably from the RefSeq database [123].
All pathogenic, likely pathogenic and VUS variants have to be reported. Secondary or inci-
dental finding (IF) is one significant matter, especially for WES, WGS and multi-gene panels, 
and its report will depend on local practice [38].
An in-house database containing all relevant variants identified in the laboratory provides an 
important tool in order to allow for further annotations, which greatly streamline the diag-
nostic process. Furthermore, an in-house database, linking patients and variants can help 
when a variant is re-classified. In this case, the laboratory is responsible for re-contacting the 
clinicians of the patients that are possibly affected by the new status of the variant [38].
4.1. Sanger sequencing validation
Concerning the limitations of technology, the false positive rate for NGS, a second method, 
as Sanger sequencing, is required to confirm any findings with possible clinical significance. 
The laboratory must be able to guarantee that report variants are true variants; therefore, it 
is essential to mention that the variant reports were confirmed by Sanger method. An NGS 
technology will likely evolve, and within a few years confirmation might prove to be unneces-
sary [34, 39].
In some cases, mainly in large panels, complementing NGS testing with Sanger sequencing is 
inevitable. This limitation of NGS is dependent on the platform and on the enrichment meth-
ods, once that there are a number of strategies available with advantages and disadvantages. 
Sanger sequencing can also be used to fill regions that fail to amplify for having sequence 
complexities, such as sequence homology with pseudo genes, highly repetitive regions, 
GC-rich content, allelic dropout, or regions that are supported by an insufficient number of 
reads to call variants confidently [34]. However, in practice, the laboratories can opt to apply 
different settings for NGS tests. Three kinds of tests of multi-genes panel are identified: (A) the 
lab informs that more than 99% of interest region are covered, and all the gaps are filled with 
Sanger sequencing; (B) the lab describes which regions are sequenced and fills some specific 
gaps (core genes) with Sanger sequencing; and (C) no additional Sanger sequencing is offered 
[38]. It is essential to mention the horizontal coverage acquired in the test and the limitations 
of these tests in a disclaimer [39].
5. Challenges
The diversity and rapid evolution of NGS technology causes many challenges associated 
with data generation, data manipulation and data storage [124]. Some of the major issues 
with analysis, interpretation, reproducibility and accessibility of NGS data includes: (A) 
NGS is still too expensive to be accessible by small labs or an individual; (B) data analysis is 
time-consuming and needs sufficient knowledge of bioinformatics; (C) the short sequencing 
read lengths supported by NGS is one of the major shortcomings which limit its application, 
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especially in de novo and highly repetitive regions sequencing; (D) data processing steps or 
bioinformatics is one major bottleneck for the implementation of NGS; (E) routine analysis 
of NGS data requires multidisciplinary teams; (F) it is critical to standardize the quality met-
rics for the NGS data generated. These include validation and comparison among platforms, 
data reliability, robustness and reproducibility, and quality of assemblers; (G) it is crucial to 
have a complete knowledge of family and personal history of the patient to help define the 
ideal analysis method, the analysis of the results obtained, and the post-test counselling and 
management [124–127].
Despite some challenges, it is hard not to be optimistic about the future of personalized 
genome sequencing and its potential impact on patient care and the advancement of knowl-
edge of human biology and disease.
5.1. Regulation on NGS tests
With the advancement of gene-sequencing technologies, numerous opportunities have arisen 
in the genetic diagnostic, preventive medicine and other areas of human health. As a result, 
several life science companies and clinical laboratories started their activities in this field 
offering equipment and supplies as well as molecular tests using the new-generation (par-
allel massive) sequencing methodology. However, most manufacturers do not market IVD 
products (in vitro diagnostic), but, in general, these products are classified as RUO (research 
use only). In practice, this difference in the classification of products and reagents represents 
serious implications on health. Products classified as IVD are regulated and therefore follow 
technical standards in their production and use, and consequently the efficiency must be guar-
anteed by the manufacturer. The ISO 13485 [128] is often used to ensure the quality of medical 
products, but other regulatory agencies such as the US Food and Drug Administration (FDA) 
may require other tests to prove this product is safe and effective, which is necessary for 
the product be classified as IVD and be commercialized on the American market. The same 
applies to the CE-IVD Marking in the European Economic Area (EEA). These requirements 
are part of an effort to ensure that users of these services and devices do not seek unneces-
sary treatment, delay their treatment or are exposed to inappropriate therapies. In the case 
of RUO products, none of these situations can be guaranteed, so the manufacturer will only 
be obliged to replace the product or its cost if it is performing improperly. In fact, some 
manufacturers may use standards of good manufacturing practice in the production of RUO 
equipment and supplies, but rarely perform tests to prove their efficiency in a particular case 
of diagnostic.
In some cases due to the need to respond quickly to the market, especially in areas where the 
technological advance exceeds the regulatory capacity, some agencies allow the use of tests 
developed by clinical laboratories. The regulation in these cases is very simpler and favours 
the development of new technologies as the case of new-generation sequencing (NGS). 
However, these tests should also be used with caution, and the laboratories must prove its 
accuracy, or otherwise there may be the same hazards of products classified as RUO. In 2013, 
the US FDA agency required to genetic testing company 23andME to suspend the marketing 
of its products until it receives clearance from the agency. In a letter addressed to one of its 
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founders, the agency states its concern about the use of one of its tests and the implications on 
the health of the patient in case of false results.
Some of the uses for which PGS (Personal Genome Service) is intended are particu-
larly concerning, such as assessments for BRCA-related genetic risk and drug responses 
(e.g., warfarin sensitivity, clopidogrel response, and 5-fluorouracil toxicity) because of 
the potential health consequences that could result from false positive or false negative 
assessments for high-risk indications such as these. For instance, if the BRCA-related 
risk assessment for breast or ovarian cancer reports is false positive, it could lead to 
undergo prophylactic surgery, chemoprevention, intensive screening, or other morbid-
ity-inducing actions, while false negative could result in failure to recognize an existing 
risk that may exist. [129]
This example illustrates the importance of evaluating the analytical characteristics of diagnos-
tic tests as well as the reagents and equipment used to perform these tests. In 2013, Illumina 
was the first company to get FDA approval for the commercialization of four NGS products. 
It was the first approval for a system based on NGS technology that will allow other com-
panies to develop their own tests using this technology. In 2014, it was the time of SOPHiA 
Genetics and Vela Diagnostics companies that obtained the CE-IVD Marking of the first prod-
ucts based on the NGS technology for clinical use.
Since then, the number of products that have the classification of IVD has been increasing; 
however, it is important to note that the classification of an IVD product depends on local 
regulations, and therefore products that are classified as IVD in a market may not have this 
classification in other markets. This is due to the regulatory differences between the agencies 
and the different requirements from each market. Anyway, it is usual that classification pro-
cess of these products for clinical use must be complex and sometimes elaborated, especially 
in areas such as genomics. Therefore, initiatives are needed to make the approval process for 
these products simpler and more flexible, to make the products available, but that ensures the 
accuracy and usefully testing.
In 2016, the US FDA agency issued two draft guidelines: ‘Use of Standards in FDA's Regulatory 
Oversight of Next Generation Sequencing (NGS) Based In Vitro Diagnostics (IVDs) Used for 
Diagnosing Germ line Diseases’ and ‘Use of Public Human Genetic Variant Databases to 
Support Clinical Validity for Next Generation Sequencing (NGS)-Based In Vitro Diagnostics’. 
Both are part of an initiative that aims to contribute to new testing using the NGS technology 
to reach the public with more speed and quality required by the market and health system.
5.2. Clinical validation
Almost all NGS approaches are still RUO, and validation is necessary before implementation 
as a diagnostic test. Prior clinical utility, a test must demonstrate analytical and clinical validity. 
Sensitivity, specificity, robustness, limits of detection, reproducibility, accuracy, precision and 
concordance between test results and clinical diagnosis should be analysed and measured. The 
test needs to evaluate patient outcomes and have positive impact on patient care [66, 130]. To assist 
the usage and implementation of NGS in clinical laboratories, some standards and best practice 
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guidelines are already available [38, 39, 44, 131–134]. Several NGS validation studies in clinical 
laboratories have been published and are rich sources of information [135–138]. Improvements 
in NGS technologies and data analysis require revalidation before implementation.
5.3. Computational infrastructure
The high volume of NGS data generated requires a complex computational infrastructure for 
processing, analysing and storing the data, including sophisticated data analysis pipelines. 
Cloud solutions such as Google, Amazon and Microsoft can be an alternative to an in-house 
computational infrastructure. More user-friendly bioinformatics software are desirable for 
non-bioinformaticians, such as Google Genomics [139], SOPHiA Genetics [140], IBM Watson 
[141], Illumina BaseSpace [142], Ion Reporter [143], Galaxy [144], CLC Genomics [145]. The 
variability of data formats generated during the analysis (e.g. FASTQ, UBAM, BAM/SAM and 
VCF files) and the laboratory must decide the appropriate data to be stored since the cost of 
managing, analysing and storing is high [124, 130, 146–149].
5.4. Genomic education
A multidisciplinary team of bioinformaticians, computational biologists, IT technicians, 
statisticians, molecular biologists, geneticists, genetic counsellors and clinicians is strongly 
needed and should be properly trained and educated for a successful implementation of NGS 
into routine diagnostic. Other related areas, such as lawyers, policy-makers, sales representa-
tive and investors, also need to be trained. Due to the constant updates of NGS approaches, 
an ongoing and continuing education about emerging technologies, software, databases and 
data analysis pipelines that reflect current practice is necessary. Genomic education also 
needs to be incorporated into medical school curriculum [148, 150].
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